

State of Oklahoma **SoonerCare**

Tecvayli™ (Teclistamab-cqyv) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Physician billing (HCPCS code:	Start Date	:
Dose:	Regimen:	
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI: Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
 B. Has member received immunomodulatory C. Please list therapies D. Is the health care far neurological toxicities E. Will the health care requirements? Yes_ 	lapsed or refractory? YesNed ≥ 4 prior lines of therapy, in agent, and an anti-CD38 antibes member has tried and failed: cility trained in the managements? Yes No facility comply with the risk evaluation.	ent of cytokine release syndrome (CRS), aluation and mitigation strategy (REMS)
Additional information:		
yes, please specify adverse Prescriber Signature: I certify that the indicated treatment	dence of progressive disease ved adverse drug reactions relative reactions: Int is medically necessary and all inform in full will result in processing of	while on teclistamab-cqyv? ted to teclistamab-cqyv? Yes NoIf

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014

Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE
This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.